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A B S T R A C T
Purpose
This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in
patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.
Patients and Methods
Patients were randomly assigned in a 1:1 ratio to linifanib 17.5 mg once daily or sorafenib 400 mg
twice daily. Patients were stratified by region (Outside Asia, Japan, and rest of Asia), Eastern
Cooperative Oncology Group performance score (ECOG PS; 0 or 1), vascular invasion or
extrahepatic spread (yes or no), and hepatitis B virus (HBV) infection (yes or no). The primary end
point of the study was overall survival (OS). Secondary end points were time to progression (TTP)
and objective response rate (ORR) per RECIST v1.1.
Results
We randomly assigned 1,035 patients (median age, 60 years; Asian, 66.6%; ECOG PS 0,
65.2%; HBV, 49.1%; vascular invasion or extrahepatic spread, 70.1%). Median OS was 9.1
months on the linifanib arm (95% CI, 8.1 to 10.2) and 9.8 months on the sorafenib arm (95%
CI, 8.3 to 11.0; hazard ratio [HR], 1.046; 95% CI, 0.896 to 1.221). For prespecified stratification
subgroups, OS HRs ranged from 0.793 to 1.119 and the 95% CI contained 1.0. Median TTP was
5.4 months on the linifanib arm (95% CI, 4.2 to 5.6) and 4.0 months on the sorafenib arm (95%
CI, 2.8 to 4.2; HR, 0.759; 95% CI, 0.643 to 0.895; P  .001). Best response rate was 13.0% on
the linifanib arm versus 6.9% on the sorafenib arm. Grade 3/4 adverse events (AEs); serious AEs;
and AEs leading to discontinuation, dose interruption, and reduction were more frequent with
linifanib (all P  .001).
Conclusion
Linifanib and sorafenib had similar OS in advanced HCC. Predefined superiority and noninferiority
OS boundaries were not met for linifanib and the study failed to meet the primary end point. TTP
and ORR favored linifanib; safety results favored sorafenib.
J Clin Oncol 33:172-179. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third most
common cause of cancer deaths worldwide, after
lung and stomach cancer.1,2 More than 75% of all
HCC cases occur in the Asia-Pacific region and are
associated with chronic hepatitis B virus (HBV) in-
fection,3,4 with an increased incidence in theUnited
States and Europe over the last decade. Despite the
available treatment options for HCC, the incidence
and mortality rates are nearly equal.5 A minority of
patients are diagnosed with resectable HCC,6,7
whereas approximately 70% to 85% of HCC pa-
tients have locally advanced unresectable or meta-
static disease at diagnosis.1,6-8 Up to 70%of patients
who undergo potentially curative procedures will
have recurrent, advanced-stage disease within 5
years.9,10 Thus, effective systemic therapies are
needed for the vast majority of patients with HCC.
HCC is a highly vascularized tumor character-
ized by overexpression of vascular endothelial
growth factor (VEGF).11 Three important proan-
giogenic factors, VEGF, platelet-derived growth fac-
tor (PDGF), and basic fibroblast growth factor, are
involved in hepatocarcinogenesis and participate in
the neovascularization, invasiveness, andmetastatic
potential of HCC.11 Elevated VEGF is associated
withpoorprognosis and survival aswell as recurrent
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disease inHCC.12VEGFreceptor1andVEGFreceptor2areexpressed
on endothelial cells and provide survival signals to nearby tumor
cells.13 PDGF is angiogenic for microvascular sprouting endothelial
cells,14 and overexpression has been linked to the increasedmetastatic
potential of HCC.15 Given that VEGF and PDGF expression is corre-
lated with metastatic potential of tumor cells and the degree of mi-
crovessel density,15-17 inhibitors of VEGF and PDGF signaling are
frequently applied agents for HCC.
Sorafenib is a multitargeted tyrosine kinase inhibitor that blocks
the activity of Raf serine/threonine kinase isoforms, VEGFR-2 and -3,
PDGFR, c-KIT, FLT-3, andRET, to inhibit tumor angiogenesis and
cell proliferation,18-20 and is currently the worldwide standard treat-
ment for advanced HCC based on data from two large randomized
trials, both showing an improvement in overall survival (OS) when
compared with placebo.21-23
Linifanib (ABT-869) is a novel ATP-competitive inhibitor of all
VEGF andPDGF receptor tyrosine kinases that lacks significant activ-
ity against representative cytosolic tyrosine kinases and serine/threo-
nine kinases.24 In an open-label, phase II trial, linifanib demonstrated
significant clinical activity as monotherapy in patients with advanced
HCC.25 The independently assessed time to progression (TTP; me-
dian, 5.4 months) and OS (median, 9.7 months) among the trial
population, 89% of whomwere of Asian race, compared favorably
with the corresponding efficacy outcomes for patients in the phase
III sorafenib trial conducted in the Asia-Pacific region.23 On the
basis of these results, we compared efficacy and tolerability of
linifanib versus sorafenib in patients with advanced or metastatic
HCC who had not received prior systemic therapy. Given the lack
of established second-line treatment options in HCC, the primary
endpoint of this studywasOS. Secondary endpointswereTTP and
objective response rate (ORR).
PATIENTS AND METHODS
Study Population
Patients ages  18 years with unresectable or metastatic HCC, Child-
Pugh Class A liver function, Eastern Cooperative Oncology Group (ECOG)
performance score (PS) of 0 to 1, adequate hepatic (bilirubin  3.0 mg/dL;
ALT/AST  5 upper limit of normal [ULN]; albumin  2.8 g/dL; partial
thromboplastin time  1.5 ULN; international normalized ratio  1.5),
hematologic (absolute neutrophil count [ANC] 1.0 109/L; platelets 50
 109/L or 75  109/L with splenomegaly [per physical examination or
reported on radiographic imaging]), and renal (creatinine  1.5 ULN)
parameters, no prior systemic treatment for HCC, and a measurable lesion
based onRECISTv1.126were eligible. Eligibility criteria also includednoprior
local therapy (including liver-directed therapy) within 4 weeks before study
drug administration and no radionuclide treatment within 6 months (or five
half-lives); no evidence of untreated brain or meningeal metastases; no evi-
dence of proteinuria at baseline; no symptomatic or persistent uncontrolled
hypertension ( 140/90 mmHg); and patients could not be receiving thera-
peutic anticoagulation therapy or antiretroviral therapy for HIV.
Study Design and Treatment
This randomized, open-label phase III study was performed at 186 sites
by 207 investigators in 28 countriesworldwide.The studywas approvedby the
institutional reviewboardor independent ethics committeeof eachparticipat-
ing center andcompliedwith the InternationalConferenceonHarmonization
Good Clinical Practice guidelines and applicable local regulatory require-
ments. All patients provided written, informed consent.
Patients were randomly assigned in a 1:1 ratio to receive linifanib or
sorafenib. Linifanib17.5mgwasorally self-administereddailywith at least 120
mLofwater under fasting conditions in the evening. Therewere no scheduled
dosing breaks; dose reductions or drug interruptions owing to study drug-
related toxicities were allowed per discretion of the investigator. Sorafenib 400
mg was orally self-administered twice daily per the locally approved product
label or applicable Summary of Product Characteristics.
Study visits were conducted weekly during the first 3 weeks and then on
day 1 every 3 weeks thereafter (starting with week 4). Patients with controlled
disease and with tolerable adverse effects received treatment until disease
progression; unacceptable drug related toxicities; or until they required
cancer-related surgery, radiation therapy, or alternate antineoplastic agents. If
a dose reduction of linifanib was needed, the dose was decreased by 5 mg for
thefirst reduction followedby2.5mg for all subsequent reductions. Sorafenib-
related toxicities were managed according to the approved product label in
that country.
Outcomes and Assessments
OSwas defined as the number of days from the day the patient received
randomassignment to the date of the patient’s death fromany cause. TTPwas
defined as the number of days from the date of randomization to the date of
earliest disease progression. Progression-free survival (PFS)was defined as the
number of days from the date of randomization to the date the patient expe-
rienced an event of disease progression or death (all causes of mortality) if
disease progression was not reached. ORR was defined as the proportion of
patientswith complete response (CR) or partial response (PR). TTP, PFS, and
ORRwere all based onRECIST, v1.1.26 Radiographic tumor assessmentswere
performed at screening, every 6 weeks until week 42, and every 9 weeks
thereafter. Treatment emergent adverse events (AEs) were summarized by
systemorgan class andpreferred termaccording to theMedicalDictionary for
Regulatory Activities (MedDRA). In addition, AEs of hemorrhage were sum-
marized based on a narrow standardized MedDRA query, excluding clinical
laboratory terms. AE severity was graded using the National Cancer Institute
Common Terminology Criteria for Adverse Events (version 4.0). When an
investigator determined that a patient should discontinue the study, a final
visit was conducted. All patients were to have one follow-up visit approxi-
mately 30 days after the last dose of linifanib or sorafenib.
Statistical Methods
In our current study, both noninferiority and superiority hypotheses
were tested. This design would allow for superiority assessment only if and
after noninferiority was achieved. Because no single prior study of linifanib
compared safety outcomes versus sorafinib, noninferiority testing was
planned in case safety data favored linifanib. Assuming the true hazard ratio
(HR) in favor of the linifanib group is 0.80, a total of 667 deaths would be
needed for the study tohave80%powerat aone-sided levelof 0.025 todetect
a statistically significant treatment effect for the linifanib group using the
log-rank test for OS. Two interim analyses, one for futility alone and one for
both efficacy and futility, were performed and reviewed by an independent
data monitoring committee when approximately 200 deaths (30% of the
required number of events) and 333 deaths (50% of the required number of
events)were observed, respectively. TheLan-DeMets alpha spending function
withanO’Brien-Flemingboundarywas tobeused toensure that theone-sided
false positive rate would be 0.025 or less for OS.
Using a noninferiority test on the primary efficacy end point of OS
with a noninferiority margin of 1.0491, the power of the study to declare
noninferiority is tabulated in the Data Supplement for the same range of
possible HRs (one interim analysis for futility alone and one interim
analysis for both efficacy and futility are assumed when approximately 200
and 333 deaths occur, respectively). The power for HRs of 0.80, 0.82, and
0.85 was 93%, 88%, 80%, and 74%, respectively.
The distribution of OS was estimated for each treatment group using
Kaplan-Meier methodology. Estimatedmedian survival time and 95%CI for
the estimatedmedian survival time were presented for each treatment group.
Both noninferiority and superiority hypotheses were tested for the primary
efficacy end point of OS using the Cox proportional hazards model with
treatment as a factor, stratified by region (outside Asia, Japan, or rest of Asia),
ECOG PS (0 v 1), vascular invasion or extrahepatic spread (yes v no), and
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hepatitisBvirus infection (yesvno).Withineach stratum,apermutated-block
randomizationmethodwasused togenerate thepatient randomizationsched-
ules. Noninferiority for OS was tested first with a margin value of 1.0491. If
noninferiority was declared for OS, then superiority was to be tested for OS.
The HR and the corresponding CI were estimated using the stratified Cox
proportional hazards model. Additional details of the statistical methods are
provided in the Data Supplement (online only).
After enrollment was complete, the data were analyzed by the indepen-
dent datamonitoring committee, at which time they recommended stopping
the trial based on futility to show superiority (HR forOS, 0.989; 95%CI, 0.821
to 1.192; 455 OS events). The investigators were notified and the study was
amended for early closure. To allow time to plan subsequent treatment, the
remaining active patients (n 184) continued on study drug per investigator
discretion. The results presented are based on the final analysis as conducted
per protocol at 667 OS events. The data cutoff was onMay 31, 2012.
RESULTS
Study Conduct, Patients, and
Treatment Administration
We randomly assigned 1,035 patients to receive linifanib 17.5
mg once daily (n  514) or sorafenib 400 mg twice per day (n 
521). The efficacy population comprised all 1,035 patients (Fig 1).
Six patients did not receive study medication and the remaining
1,029 patients (linifanib, n 510; sorafenib, n 519) received at
least one dose of study medication and made up the safety analysis
population (Fig 1). The treatment arms were well balanced for
demographic, disease, prior treatment characteristics and stratifi-
cation subgroups (Table 1). Overall, most patients were male
(84.6%), Asian (66.6%), had HBV infection (53.2%), Child-Pugh
Class A liver function (94.4%), ECOGPS 0 (64.4%), and Barcelona
Clinic Liver Cancer stage C HCC (82.3%).
Patients’ mean duration of exposure to linifanib and sorafenib
was 127.2 days (range, 2 to 775 days) and 127.8 days (range, 3 to 729
days), respectively (Appendix Table A1 [online only]). No statistically
significant differences in duration of exposurewere observed between
treatment groups. Patients’ mean daily dose was 13.7 mg for the
linifanib arm (standard deviation, 4.42 mg) and 667.1 mg for the
sorafenib arm (standard deviation, 164.36 mg). The mean linifanib
dose-intensity was 78.2% and the mean sorafenib dose-intensity was
83.4%,whichwas significantlyhigher (P .001).Ofpatients receiving
linifanib or sorafenib, 55.9% and 40.8%, respectively, had a dose
reduction. Themost common reasons for study drugdiscontinuation
were disease progression (linifanib arm, 68.6%; sorafenib arm62.0%)
and AEs not related to progressive disease (linifanib arm, 15.2%;
sorafenib arm, 22.9%; Fig 1).
Efficacy
Median OS was 9.1 months (95% CI, 8.1 to 10.2) for patients
receiving linifanib and 9.8 months (95% CI, 8.3 to 11.0) for patients
receiving sorafenib (Fig 2). Compared with the sorafenib group, the
median stratified HR was 1.046 (95% CI, 0.896 to 1.221) for the
linifanib group (Fig 2). OS was not superior with linifanib treatment.
Furthermore, the HR 95% CI upper limit of 1.221 did not meet the
prespecified studydefinitionof linifanibnoninferiority (upper limitof
HR 95%CI 1.0491). We conducted analyses of OS by prespecified
stratification subgroups (region: outside Asia, Japan, or rest of Asia;
baseline ECOGPS: 0 v 1; vascular invasion or extrahepatic spread: yes
vno; andHBV infection: yes vno). For all prespecified subgroups, the
OSHRs ranged from0.793 to1.119 and the95%CIcontained1.0 (Fig
3). Therefore, OSwas similar across all prespecified subgroups. Over-
all death rates were similar between the linifanib group (66.5%) and
sorafenib group (65.3%).
Patients were screened
(N = 1,358)
Randomly assigned
(n = 1,035)
Assigned to receive linifanib (intention-to-treat population)
(n = 514)
Assigned to receive sorafenib (intention-to-treat population)
(n = 521)
Received sorafenib (safety population)
(n = 519)
Received linifanib (safety population)
(n = 510)
All discontinued study drug
    Disease progression
    AE not related to PD
    Withdrew consent
    Lost to follow-up
    Because of other reason
    Because of study discontinuation
(n = 316)
(n = 117)
(n = 35)
(n = 3)
(n = 12)
(n = 27)
All discontinued study drug
    Disease progression
    AE not related to PD
    Withdrew consent
    Lost to follow-up
    Because of other reason
    Because of study discontinuation
 
(n = 356)
(n = 79)
(n = 23)
(n = 7)
(n = 13)
(n = 41)
Withdrew consent
Other
(n = 1)
(n = 1)
Withdrew consent
Other
(n = 2)
(n = 2)
Failed screening
    Had protocol exclusion criteria
    Withdrew consent
    Had an adverse event
    Not treated due to progression
    Died
    Lost to follow-up
    Other
(n = 323)
(n = 271)
(n = 29)
(n = 2)
(n = 4)
(n = 3)
(n = 2)
(n = 12)
Fig 1. CONSORT diagram. AE, adverse event; PD, progressive disease.
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Table 1. Baseline Patient and Disease Characteristics
Characteristic
Linifanib (n  514) Sorafenib (n  521)
No. of Patients % No. of Patients %
Age, years
Median 59 60
Range 21-84 23-87
Male sex 444 86.4 436 83.7
Region
Outside Asia 175 34.0 171 32.8
Japan 40 7.8 44 8.4
Rest of Asia 299 58.2 306 58.7
Underlying risk factors for cirrhosis†
HBV 275 53.5 276 53.0
HCV 130 25.3 129 24.8
Alcohol cirrhosis 66 12.8 63 12.1
Hemochromatosis 5 1.0 4 0.8
Other 103 20.0 116 22.3
ECOG performance status†
0 323 62.8 344 66.2
1 191 37.2 176 33.8
Child-Pugh class‡
A 484 93.2 493 95.0
B 30 5.8 26 5.0
BCLC stage
B 81 15.8 102 19.6
C 433 84.2 418 80.4
Vascular invasion†
Yes 238 46.3 211 40.5
Extrahepatic spread†
Yes 307 59.7 296 56.8
No. of target lesions at baseline
1 129 24.8 111 21.4
2 233 46.5 247 47.7
3 70 13.7 103 19.9
 4 75 14.6 57 11.0
Sites of extrahepatic spread
Lung 172 33.5 152 29.2
Lymph node 142 27.6 132 25.3
Brain 1 0.2 0 0
Bone 40 7.8 52 10.0
Peritoneum 21 4.1 17 3.3
Other 54 10.5 52 10.0
Prior locoregional therapies
Yes 233 45.3 241 46.3
Prior oncology surgery 157 30.1
Yes 153 29.1
-fetoprotein, ng/mL§
Median 352 415
 ULN
No. of patients 430 448
% 84.8 86.3
Hepatitis B infection
No 263 51.2 264 50.7
Yes 251 48.8 257 49.3
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CRF, case report form; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C
virus; IVRS, interactive voice response system; ULN, upper limit of normal.
Patients with multiple hepatic histories were counted for each type of hepatic history.
†Per electronic CRF.
‡Child-Pugh class was determined from assessments most proximal to the beginning of treatment. Per protocol, patients were Child-Pugh class A
before randomization.
§Percentages calculated on nonmissing values.
Data from IVRS, which were used for stratification. Other stratification factors from IVRS are shown in Figure 3.
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Median TTP was 5.4 months for patients receiving linifanib
(95% CI, 4.2 to 5.6) and 4.0 months for patients receiving sorafenib
(95% CI, 2.8 to 4.2; Fig 4). Compared with the sorafenib group, the
stratified HR was 0.759 for the linifanib group (95% CI, 0.643 to
0.895), which was statistically significant (P .001). The TTP advan-
tage for linifanib was maintained until approximately 400 days of
treatment; however, once the number of at-risk patients was reduced
to fewer than 30 in each arm, the estimated probability of progression
favored the sorafenib arm for the remainingpatients.MedianPFSwas
4.2months for patients receiving linifanib (95%CI, 4.1 to 5.4) and 2.9
months for patients receiving sorafenib (95% CI, 2.8 to 4.0). Com-
pared with the sorafenib arm, the stratified HR was 0.813 for the
linifanib arm (95%CI, 0.697 to 0.948), which was statistically signifi-
cant (P .008). ForTTP inprespecified subgroups, the upper limit of
the 95%CIof theHR for linifanib versus sorafenibwas less than 1.0 in
patients in Asia (excluding Japan) who had a baseline ECOG PS of 0
and HBV infection (Appendix Fig A1 [online only]). Therefore, TTP
seemed to be significantly more favorable with linifanib than with
sorafenib in these three prespecified subgroups; TTPwas similar with
either treatment in the other subgroups.
A total of 67 patients receiving linifanib (13.0%) and 36 patients
receiving sorafenib (6.9%)hadaCRorPRperRECIST, v1.1 (Table2).
A total of 52 patients receiving linifanib (10.1%) and 32 patients
receiving sorafenib (6.1%) had a confirmed ORR (CR or PR), which
was significantly different between treatment groups (P  .018)
(Table 2).
Safety
The overall safety summary and specific grade 3/4AEs occurring
inmore than 3%of patients in either treatment armare listed inTable
3. Grade 3/4 AEs; serious AEs; and AEs leading to discontinuation,
dose interruption, or reduction were more frequent on the linifanib
arm versus the sorafenib arm (all P .001). Of the patients receiving
sorafenib, 75.0% experienced a grade 3 AE or higher; of the patients
receiving linifanib 85.3% did so. Grade 3/4 AEs that were observed
more frequently on the linifanib arm than the sorafenib arm(P .05)
were hypertension (20.8% v 10.6%), fatigue (9.6% v 4.8%), hepatic
encephalopathy (7.3% v 3.3%), asthenia (7.1% v 2.1%), ascites (6.1%
v 3.3%), thrombocytopenia (5.3% v 2.1%), hypokalemia (4.7% v
2.3%),vomiting(4.3%v0.8%),andhypoglycemia(3.1%v0.8%).The
Favor
Linifanib
Favor
Sorafenib
20 1
HR (95% CI)
Regions
   Non-Asia 
   Japan 
   Rest of Asia 
Baseline ECOG
   0 
   1 
VI or EHS
   No 
   Yes 
Hepatitis B Infection
   No 
   Yes 
Overall 
0.844 to 1.456
0.469 to 1.342
0.857 to 1.258
0.834 to 1.216
0.855 to 1.409
0.622 to 1.130
0.940 to 1.332
0.897 to 1.381
0.782 to 1.190
0.894 to 1.208
1.108
0.793
1.038
1.007
1.098
0.838
1.119
1.113
0.965
1.039
12.4
9.5
8.5
10.2
8.5
11.9
8.5
11.5
8.2
9.8
101/171
30/44
209/306
217/342
123/179
93/157
247/364
162/264
178/257
340/521
11.3
14.8
8.2
10.2
7.2
14.2
7.9
10.4
7.9
9.1
106/175
27/40
209/299
217/333
125/181
81/152
261/362
168/263
174/251
342/514
Event/No. Median (mo)
Linifanib
Event/No. Unstratified HR 95% CIMedian (mo)
Sorafenib
Fig 3. Analysis of overall survival by prespecified stratification subgroups, per interactive voice response system for stratification factors. ECOG, Eastern Cooperative
Oncology Group; EHS, extrahepatic spread; HR, hazard ratio; mo, months; VI, vascular invasion.
0
Pr
og
re
ss
io
n 
Fr
ee
 (p
ro
ba
bi
lit
y)
Time Since Random Assignment (days)
1.0
0.8
0.6
0.4
0.2
56 112 168 224 280 336 392 448 504 560 616 672 728 784
Sorafenib
Linifanib
Sorafenib
Linifanib
1
2
4
9
409
392
346
333
285
277
240
227
200
184
137
131
98
95
62
72
45
55
29
34
14
16
475
468
521
512
Overall Survival
Linifanib
Sorafenib
9.1
9.8
8.1 to 10.2
8.3 to 11.0
Median (months)
Median Stratified HR, 1.046 (95% CI, 0.896 to 1.221)
95% CI
Fig 2. Kaplan-Meier analysis of overall survival with a cutoff point at the 667th
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Fig 4. Kaplan-Meier analysis of time to progression. HR, hazard ratio.
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onlygrade3/4AEobservedmore frequentlyon the sorafenibarmthan
the linifanib arm (P .05) was increased ALT (4.8% v 2.2%). On the
linifanib arm, 52.4% of patients experienced a serious AE and 36.3%
of patients experienced an AE that led to discontinuation of study
drug. On the sorafenib arm, 38.5% of patients experienced a serious
AE and 25.4% of patients experienced an AE that led to discontinua-
tion of study drug. An AE of hemorrhage (all-grade bleeding event)
was experienced by 27.3%of patients receiving linifanib and 17.7%of
patients receiving sorafenib, the most common of which were epi-
staxis and gingival bleeding.
DISCUSSION
Our phase III trial, comparing the efficacy of oral linifanib to that of
sorafenib, failed to meet the primary end point: OS was not signifi-
cantly different between the two treatments. Median OS was 9.1
months for linifanib (95% CI, 8.1 to 10.2) and 9.8 months for
sorafenib (95%CI, 8.3 to 11.0). OS was similar across all prespecified
subgroupanalyses (region:outsideAsia, Japan,or rest ofAsia; baseline
ECOGPS: 0 v1; vascular invasionor extrahepatic spread: yes vno; and
HBV infection: yes v no).
Todate, sorafenib is the only approved systemic drug therapy for
patients with advanced HCC. Based on the increasing knowledge of
the large number ofmolecular pathways involved inHCC, numerous
targets specific and/or broad spectrum tyrosine kinase inhibitors have
beendeveloped and tested infirst- and second-line therapy. So far, the
results have been, at best, somewhat disappointing. The phase III trial
of sunitinib versus sorafenibwas terminated early owing to safety and
lackof efficacy (medianOS, 7.9 v 10.2months;HR, 1.30).27 Thephase
III trial of brivanib versus sorafenib also did not meet its primary end
point of noninferiority in OS.28 In addition, brivanib also failed to
improve OS when compared with placebo in second-line HCC treat-
ment.29 Adding other tyrosine kinase inhibitors to sorafenib also
failed, so far, to improve clinical outcomes; anexampleof thiswere the
results of a study that explored adding erlotinib to sorafenib (median
OS,9.5v8.5months;HR,0.929).30Whether tyrosinekinase inhibitors
targeting theMETsignal transductionpathwaywill improveoutcome
for patients with advanced HCC is currently being investigated in
second-line treatment studies.31
The secondary objectives of our studywere to assess theTTP and
ORRof linifanib comparedwith sorafenib. Patients receiving linifanib
had a significantly longer TTP than patients receiving sorafenib (P
.001). ORR was also significantly higher on linifanib compared with
sorafenib (P .018). The response rates according toRECISTv1.1 for
linifanib (13.0%) and sorafenib (6.9%) each compare favorably to
previous phase III trials of sorafenib in advanced HCC patients.21,23
Unfortunately, the improvements in TTP, PFS, and ORR did not
translate to improvements inOS, afinding thathasbeenreportedwith
another antiangiogenic agent in the treatment of HCC.29 TTP was
chosenas akey secondaryendpoint todetermine theeffectof linifanib
Table 2. Secondary End Points: TTP or ORR
End Point
Linifanib 17.5 mg Once
Daily (n  514)
Sorafenib 400 mg Twice
per Day (n  521)
TTP
Median 5.4 4.0
95% CI 4.2 to 5.6 2.8 to 4.2
Disease progression
events
No. of patients 278 327
% 54.1 62.8
HR 0.759
95% CI 0.643 to 0.895
P† .001
Best response rate, %‡ 13.0 6.9
Abbreviations: HR, hazard ratio; ORR, objective response rate; TTP, time
to progression.
Stratified Cox proportional hazards model for comparison with
sorafenib group.
†Stratified log-rank test (two sided).
‡Confirmed response rates were 10.1% and 6.1%, respectively.
Table 3. Safety Summary
Adverse Event
Linifanib 17.5 mg
Once Daily
(n  510)
Sorafenib 400
mg Twice per
Day (n  519)
No. of
Patients %
No. of
Patients %
Any AE 508 99.6 511 98.5
Any AE that could be related to
SD 483 94.7 481 92.7
Any AE grade  3 435 85.3 389 75.0
Any serious AE 267 52.4 200 38.5
Any AE leading to SD
discontinuation 185 36.3 132 25.4
Any AE leading to SD
interruption 389 76.3 261 50.3
Any AE leading to SD reduction 231 45.3 162 31.2
Any fatal AEs 83 16.3 73 14.1
Deaths 351 68.8 338 67.1
Grade 3 or 4 AEs occurring in
 3% of patients in either
arm
Hypertension 106 20.8 45 10.6
Palmar-plantar
erythrodysesthesia
syndrome 70 13.7 77 14.8
AST increased 62 12.2 65 12.5
Diarrhea 61 12.0 48 9.2
Fatigue 49 9.6† 25 4.8
Hepatic encephalopathy 37 7.3† 17 3.3
Asthenia 36 7.1 11 2.1
Hyperbilirubinemia 32 6.3 21 4.0
Ascites 31 6.1† 17 3.3
Thrombocytopenia 27 5.3† 11 2.1
Hypokalemia 24 4.7† 12 2.3
Blood bilirubin increased 23 4.5 18 3.5
Abdominal pain 23 4.5 14 2.7
Decreased appetite 22 4.3 13 2.5
Vomiting 22 4.3 4 0.8
Neutropenia 20 3.9 12 2.3
Hyponatremia 19 3.7 17 3.3
Leukopenia 18 3.5 12 2.3
Platelet count decreased 17 3.3 10 1.9
Hypoglycemia 16 3.1† 4 0.8
Anemia 15 2.9 28 5.4
ALT increased 11 2.2 25 4.8†
Abbreviations: AE, adverse event; SD, study drug.
P  .001 for comparison between the sorafenib and linifanib groups.
†P  .05 for comparison between the sorafenib and linifanib groups.
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on tumor progression. The link between tumor progression and sur-
vival in HCC may be complicated because of the competing risk of
death as a result of liver dysfunction.29
Agreaterportionofpatients receiving linifanib than those receiv-
ing sorafenib experienced AEs that were grade 3; serious; or led to
the reduction, interruption, or discontinuation of the study drug. The
most frequent grade 3/4 AEs were hypertension and palmar-plantar
erythrodysesthesia syndrome. The AEs reported in our study are sim-
ilar to those seen in other studies of linifanib and with other agents in
the VEGF/PDGF receptor tyrosine kinase inhibitor class.23,27,29
In summary, linifanib and sorafenib resulted in similar OS in
advancedHCC.Predefined superiority andnoninferiorityOSbound-
aries were not met for linifanib, and the study failed to meet the
primary end point. TTP and ORR favored linifanib whereas safety
results favored sorafenib.
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ASCO CancerLinQ: Unlocking Data to Transform Cancer Care
CancerLinQ, a historic undertaking from ASCO, is a rapid learning system that will unlock data from millions of patients with
cancer to help guide treatment. Oncologists will be able to consult a robust database that will pinpoint patient
characteristics, treatments, and outcomes to provide personalized suggestions that are based on similar cases.
CancerLinQ will:
● Advance the quality of cancer care
● Improve personalized treatment decisions made by cancer care teams by capturing patient information at the point of
care
● Educate and empower patients by linking them to their cancer care teams and providing personalized educational
information
● Create a powerful new data source
● Generate new ideas for clinical research
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Appendix
Table A1. Summary of Drug Exposure
Drug Exposure
Linifanib (n  514) Sorafenib (n  521)
No. of Patients % No. of Patients %
Duration of study drug, days
Mean 127.2 127.8
Median 87 84
Range 2-775 3-729
Duration, interval days
 0-21 77 15.1 54 10.4
 21-42 62 12.2 93 17.9
 42-63 55 10.8 83 16.0
 63-84 47 9.2 37 7.1
 84-105 48 9.4 42 8.1
 106 221 43.3 210 40.5
Average daily dose, mg
Mean 13.7 667.1
Median 13.8 765.9
Range 3.2-70 200-800
Dose-intensity, %
Mean 78.2 83.4
Median 78.8 95.7
Range 18.6-400 25-100
Favor
Linifanib
Favor
Sorafenib
20 1
HR (95% CI)
Regions
   Non-Asia 
   Japan 
   Rest of Asia 
Baseline ECOG
   0 
   1 
VI or EHS
   No 
   Yes 
Hepatitis B Infection
   No 
   Yes 
Overall 
0.764 to 1.420
0.433 to 1.207
0.580 to 0.869
0.644 to 0.947
0.699 to 1.244
0.565 to 1.041
0.705 to 1.027
0.814 to 1.324
0.522 to 0.802
0.706 to 0.972
1.042
0.723
0.710
0.781
0.932
0.767
0.851
1.038
0.647
0.828
5.8
2.7
2.8
3.4
4.1
4.1
4.0
5.4
2.7
4.0
91/171
29/44
207/306
229/342
98/179
94/157
233/364
140/264
187/257
327/521
5.4
4.2
5.5
5.5
4.8
5.6
4.3
5.5
5.4
5.4
73/175
32/40
173/299
189/333
189/181
73/152
205/362
124/263
154/251
278/514
Event/No. Median (mo)
Linifanib
Event/No. Unstratified HR 95% CIMedian (mo)
Sorafenib
Fig A1. Analysis of time to progression by prespecified stratification subgroups, per interactive voice response system for stratification factors. ECOG, Eastern
Cooperative Oncology Group; EHS, extrahepatic spread; HR, hazard ratio; mo, months; VI, vascular invasion.
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